Pediatric Cancers | Topics

 
Opsoclonus-Myoclonus–Associated Neuroblastoma With Bone Marrow Metastases: What Would Be the Best Treatment Option?
October 22, 2021

In this clinical quandary, investigators determine how to best treat patients with opsoclonus-myoclonus–associated neuroblastoma with bone marrow metastases.

Vincristine/Irinotecan Plus Temozolomide Shows Improved Efficacy in Relapsed/Refractory Rhabdomyosarcoma
October 14, 2021

The addition of temozolomide to vincristine and irinotecan appears to be a new standard of care for adult and pediatric patients with relapsed/refractory rhabdomyosarcoma, according to the European Paediatric Soft Tissue Sarcoma Group.

FDA Grants Rare Pediatric Disease Designation to 177Lu-omburtamab-DTPA for Medulloblastoma
October 11, 2021

Pediatric patients with medulloblastoma may experience benefit from 177Lu-omburtamab-DTPA, which was granted a rare pediatric disease designation by the FDA.

Infusion of HER2-Specific CAR T Cells into Brain or CNS “Feasible” in Pediatric Patients
September 27, 2021

ASTCT recently published an article in their journal Nucleus detailing CAR T-cell in pediatric patients with brain cancer.

Focal 22q11.22 Deletions Associated With Poor Outcomes in Pediatric B-Cell Acute Lymphoblastic Leukemia With IKZF1 Alterations
September 08, 2021

A recent study provides evidence showing that focal 22q11.22 deletions may be correlated with poor outcomes in patients with pediatric B-cell acute lymphoblastic leukemia with alterations in IKZF1.

Vincristine/Dexamethasone Pulse Therapy May be Omitted After 1 Year of Treatment in Pediatric Acute Lymphoblastic Leukemia
September 03, 2021

Pediatric patients with low-risk acute lymphoblastic leukemia may be able to omit treatment with vincristine and dexamethasone pulse therapy after the first year of treatment.

Study on Racial and Ethnic Disparities in Pediatric Cancer Identify Difference in Risk Between Patient Subgroups
July 30, 2021

Racial and ethnic disparities in incidence and risk of childhood cancer have been identified across a number of malignancies.

Pediatric Locally Advanced Synovial Sarcoma: What Would Be the Best Treatment Option?
February 11, 2021

KEY POINTS • Synovial sarcomas are often mistreated with unplanned tumor resection. • Attention from specialists early in the course of SS can minimize the risk of recurrence, metastases, and the necessity for resurgery, all of which are increased with unplanned tumor resection. • Chemotherapy alone does not provide sufficient local control of the tumor. • Resurgery, in conjunction with radiotherapy and chemotherapy, is the best choice of management for this patient.

TBI Plus Etoposide Prior to HSCT Leads to Improved OS, Lower Relapse Risk in High-Risk Pediatric ALL
January 19, 2021

Based on recent study results, investigators recommended TBI plus etoposide for patients older than 4 years of age with high-risk ALL undergoing allogeneic hematopoietic stem cell transplantation.

Gwendolyn P. Quinn, PhD, on Sexual Health in AYA Cancer Survivors
January 08, 2021

“As the number of AYA survivors continues to grow, there is a pressing need for targeted information, education, and intervention around sexual health, intimate relationships, and body image,” the Children’s Oncology Group (COG) AYA Oncology Discipline Committee wrote in a review.